Celldex Q3 2024 Earnings Report
Key Takeaways
Celldex reported a net loss of $42.1 million, or ($0.64) per share, for the third quarter of 2024. Total revenue was $3.2 million, and research and development expenses were $45.3 million. Cash, cash equivalents, and marketable securities totaled $756.0 million as of September 30, 2024.
Cash, cash equivalents and marketable securities were $756.0 million as of September 30, 2024.
Total revenue was $3.2 million in the third quarter of 2024.
Research and development expenses were $45.3 million in the third quarter of 2024.
Net loss was $42.1 million, or ($0.64) per share, for the third quarter of 2024.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.